Although SGLT2 inhibitors are standard-of-care treatments for CKD, type 2 diabetes, and heart failure (HF), the drugs are underutilized in clinical practice.
A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback